Joseph K. Belanoff net worth and biography

Joseph Belanoff Biography and Net Worth

Dr. Belanoff is the co-founder of Corcept Therapeutics and has served as a member of its Board and as its Chief Executive Officer since 1999. In 2014, he was also appointed President. Dr. Belanoff is currently a clinical faculty member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. Dr. Belanoff received his BA from Amherst College and his MD from Columbia University’s College of Physicians & Surgeons.

What is Joseph K. Belanoff's net worth?: The estimated net worth of Joseph K. Belanoff is at least $142.37 million as of July 6th, 2022. Dr. Belanoff owns 2,538,218 shares of Corcept Therapeutics stock worth more than $142,368,648 as of November 20th. This net worth approximation does not reflect any other investments that Dr. Belanoff may own. Additionally, Dr. Belanoff receives a salary of $2,430,000.00 as CEO at Corcept Therapeutics. Learn More about Joseph K. Belanoff's net worth.
How old is Joseph K. Belanoff?: Dr. Belanoff is currently 67 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. Learn More on Joseph K. Belanoff's age.
What is Joseph K. Belanoff's salary?: As the CEO of Corcept Therapeutics Incorporated, Dr. Belanoff earns $2,430,000.00 per year. Learn More on Joseph K. Belanoff's salary.
How do I contact Joseph K. Belanoff?: The corporate mailing address for Dr. Belanoff and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Joseph K. Belanoff's contact information.
Has Joseph K. Belanoff been buying or selling shares of Corcept Therapeutics?: Joseph K. Belanoff has not been actively trading shares of Corcept Therapeutics during the last ninety days. Most recently, Joseph K. Belanoff sold 279,908 shares of the business's stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $26.27, for a transaction totalling $7,353,183.16. Following the completion of the sale, the chief executive officer now directly owns 2,538,218 shares of the company's stock, valued at $66,678,986.86. Learn More on Joseph K. Belanoff's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 269,472 shares worth more than $7,991,445.07. The most recent insider tranaction occured on November, 11th when Director Daniel N. Swisher, Jr. sold 2,200 shares worth more than $131,736.00. Insiders at Corcept Therapeutics own 20.5% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 11/11/2024.

Joseph K. Belanoff Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/6/2022	Sell	279,908	$26.27	$7,353,183.16	2,538,218
12/12/2018	Sell	217,115	$19.01	$4,127,356.15	2,381,310
11/11/2016	Sell	500,000	$8.98	$4,490,000.00	2,464,195
11/7/2016	Sell	500,000	$8.31	$4,155,000.00	2,257,728

Joseph K. Belanoff Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $56.09

$54.02

$56.13

50 Day Range

MA: $47.62

$35.71

$59.60

2 Week Range

Now: $56.09

$20.84

$61.66

Volume

1,013,492 shs

Average Volume

1,182,597 shs

Market Capitalization

$5.88 billion

P/E Ratio

44.52

Dividend Yield

N/A

Beta

0.45

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late

Joseph Belanoff Biography and Net Worth

What is Joseph K. Belanoff's net worth?

How old is Joseph K. Belanoff?

What is Joseph K. Belanoff's salary?

How do I contact Joseph K. Belanoff?

Has Joseph K. Belanoff been buying or selling shares of Corcept Therapeutics?

Who are Corcept Therapeutics' active insiders?

Are insiders buying or selling shares of Corcept Therapeutics?